Skip to main content
SpringerLink
Log in

Rapid reduction of nasal melanoma by nivolumab

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–30.

    Article  CAS  PubMed  Google Scholar 

  2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56–61.

    Article  CAS  PubMed  Google Scholar 

  4. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or- naïve melanoma. J Clin Oncol 2013; 31: 4311–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2016; 27: 434–41.

    Article  CAS  PubMed  Google Scholar 

  7. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffinembedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016; 22: 433–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    Kohei Nojima, Takeshi Namiki, Keiko Inui, Takaaki Hanafusa & Hiroo Yokozeki

  2. Department of Pathology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    Keiko Miura

  3. Department of Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    Takahiro Asakage

Authors
  1. Kohei Nojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Namiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiko Inui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takaaki Hanafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiko Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Asakage
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroo Yokozeki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Namiki.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nojima, K., Namiki, T., Inui, K. et al. Rapid reduction of nasal melanoma by nivolumab. Eur J Dermatol 26, 405–406 (2016). https://doi.org/10.1684/ejd.2016.2789

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2016.2789

Search

Navigation